바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.71 No.3
Citation Share

Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2011, v.71 no.3, pp.210-215

Young Jin Yuh (Inje University)
Byung Gyu Kim (Inje University)
(Inje University)
Sung Kyun Cho (Inje University)
(Inje University)
Sung Rok Kim (Inje University)
Young, J. Y. , Byung, G. K. , Sung, K. C. , & Sung, R. K. (2011). Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients. Tuberculosis & Respiratory Diseases, 71(3), 210-215.
  • Downloaded
  • Viewed
PDF Download

Abstract

Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.

keywords
imatinib mesylate, Lung Diseases, Interstitial, Chronic Myeloid Leukemia

Reference

1.

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96: 3343-56.

2.

2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53.

3.

3. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009;84:287-93.

4.

4. Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-75.

5.

5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.

6.

6. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-9.

7.

7. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4.

8.

8. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21: 3171-3.

9.

9. Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneu monitis following long-term imatinib administration. Intern Med 2007;46:1941-2.

10.

10. Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59: 423-6.

11.

11. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy